Phase Holographic Imaging (PHI) and Wake Forest Institute for Regenerative Medicine (WFIRM) recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs. Based on PHI's non-invasive HoloMonitor technology, the two entities jointly aim to develop imaging techniques for assessing cell culture quality in industrial biomanufacturing. The initiative is possible via WFIRM's collaborative work with the RegeneratOR Test Bed program.

The RegenMed Development Organization (ReMDO), a non-profit organization dedicated to accelerating the discovery and translation of regenerative medicine therapies, manages the RegeneratOR program. Together with technology partners like PHI, the RegeneratOR Test Bed seeks to assist regenerative medicine start-ups and growth companies with new and emerging technologies through access to advanced biomanufacturing equipment, talent and programs. WFIRM plans to provide regenerative medicine infrastructure and expertise, whereas PHI provides imaging expertise together with associated resources. Legally, the Wake Forest School of Medicine and its Public Health Sciences division sign the letter of intent on behalf of WFIRM.